Previous studies have uncovered mutations in various genes that frequently co-occur with ATRX mutations in ALT-positive cancers, such as TP53, IDH1 and H3F3A, making them candidates for promoting ALT activity [10, 39–41]. Here, ATRX is linked to cancer.